The opportunity presented to the biosimilars market with the article stating that “numerous biologic therapies with total revenues of $37B will have lost patent protection by 2017, promising considerable opportunity in biosimilars (government-approved new versions of branded biopharmaceutical products following patent expiration),”
Harry Glorikian, managing partner of Scientia Advisors, stated, “With the market for biologic* drugs growing much faster than that of drugs based on chemical compounds, pharmaceutical, biotechnology, generic drug and contract manufacturing companies are repositioning and forming new alliances in order to succeed in a rapidly changing landscape.”
Read the full article here.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment